The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer

C. J. Fabian

**Introduction**

Estrogen promotes the growth and survival of normal and cancerous breast epithelial cells by binding and activating the estrogen receptor (ER). The activated receptor in turn binds to gene promoters in the nucleus and activates many other genes responsible for cell division, inhibition of cell death, new blood vessel formation and protease activity. An increase in the proportion of cells that express ER is found at both the earliest stages of breast precancer and in approximately 70% of breast cancers (1). There are three ways in which estrogen-dependent processes important in the development and progression of the majority of breast cancers may be interrupted (Figure 1). The first is to interfere with the binding of estrogen to the ER and/or to the promoter elements of the genes it regulates. Selective ER modulators such as tamoxifen and raloxifene act in this manner. A second method is to reduce or eliminate ER expression. This is exemplified by fulvestrant, a selective ER down-regulator, which works by making less receptor available for binding to estrogen. The most direct means is to simply reduce the amount of estrogen by interfering with its production, via ovarian ablation in premenopausal women and use of aromatase inhibitors or inactivators (AIs) in postmenopausal women. Because of their effectiveness, AIs are quickly becoming the most frequently used antihormonal treatment for breast cancer in postmenopausal women. Further, AIs are now being tested in breast cancer prevention trials.

Aromatase inhibitors are not without adverse effects, which primarily stem from profound estrogen depletion. Many women will turn to their internists for advice about whether to take these drugs, as well as help in preventing and managing adverse events. The purpose of this article is to provide primary care physicians with a basic understanding of AIs to help facilitate these interactions.

**What is an aromatase inhibitor and how does it work?**

Aromatase inhibitors and inactivators interfere with the body’s ability to produce estrogen from androgens by suppressing aromatase enzyme activity.
Before menopause, ovarian aromatase is responsible for the majority of circulating estrogen and is exquisitely sensitive to changes in luteinising hormone (LH). Following menopause, aromatase in fat and muscle may be responsible for much of the circulating estrogen. Aromatase in highly estrogen-sensitive tissues, such as the breast, uterus, vagina, bone, brain, heart and blood vessels, provides local estrogen in an autocrine fashion (Figure 2). The aromatase gene promoter in breast tissue is less sensitive than the gene promoter in the ovary to fluctuations in LH but much more sensitive to increases in inflammatory cytokines. Circulating inflammatory cytokines increase with age, and breast tissue inflammatory cytokines increase with proliferative breast disease and breast cancer. Thus, it comes as little surprise that breast aromatase activity is increased in proliferative breast disease and many cases of breast cancer (2).

Three generations of AIs have been developed (Table 1) (3–8). Each successive generation has been associated with higher specificity for the aromatase enzyme (Figure 3), fewer adverse events, and greater suppression of aromatase activity. The utility of first- and second-generation AIs was limited by adverse events, such as rash, fatigue, dizziness, ataxia, nausea and vomiting, as well as by a lack of enzyme selectivity. Third-generation AIs are superior to earlier versions because they are associated with fewer adverse events and greater suppression of aromatase activity. There are two classes of third-generation AIs. Non-steroidal AIs reversibly bind to the aromatase enzyme and include letrozole and anastrozole. The steroidal AI exemestane binds to aromatase irreversibly. All third-generation AIs are administered orally on a daily basis. Adverse events include hot flushes, vaginal dryness, loss of libido, fatigue, arthralgias, joint stiffness and loss of bone mineral density with subsequent increased risk of fracture (9). In premenopausal women, AIs have a limited ability to reduce circulating estrogen. Unlike postmenopausal women, premenopausal women have a large amount of aromatase substrate present in the ovary. The exquisite sensitivity of the ovarian aromatase promoter to gonadotrophins, which increase dramatically after AI administration, makes AIs less effective in inhibiting ovarian estrogen production. Thus, AIs are generally not given to premenopausal women for breast cancer.

![Figure 1](image1.png)

**Figure 1** Schematic of metabolic pathways in an ER-positive cell that can be affected by AIs. The left side represents the active pathways and cellular responses under normal estrogen control. The right side depicts the blockade of pathways involving ERs and the resultant cellular responses. AI, aromatase inhibitor; E2, estradiol; ER, estrogen receptor; MAP, mitogen-activated protein; PI-3, phosphoinositide-3; RTK, receptor tyrosine kinase; SERD, selective estrogen receptor down-regulator; SERM, selective estrogen receptor modulator.

![Figure 2](image2.png)

**Figure 2** Schematic of organs with substantial aromatase activity.

![Table 1](table1.png)

**Table 1** Efficacy of aromatase suppression by three generations of AIs

| Drug                   | Dose | % Inhibition |
|------------------------|------|-------------|
| **First generation**   |      |             |
| Aminoglutethimide      | 1 g  | 91          |
| **Second generation**  |      |             |
| Fadrozole              | 2 mg | 82          |
| Vorozole               | 1 mg | 93          |
| **Third generation**   |      |             |
| Letrozole              | 2.5 mg | 99        |
| Anastrozole            | 1 mg | 97          |
| Exemestane             | 25 mg| 98          |

AIs, aromatase inhibitors.
treatment without the addition of a medication to suppress the rise in gonadotrophins and subsequent increase in hormone levels (9).

**Why do we need aromatase inhibitors?**

For women with newly diagnosed hormone receptor positive ER+ cancers requiring systemic adjuvant therapy, 5 years of tamoxifen reduces the relative odds of recurrence by 40% and relative risk of death from breast cancer by 34% (10). At 15 years this equates to about a 12% absolute reduction in recurrence and a 9% absolute reduction in mortality, irrespective of nodal status. However, about a third of women diagnosed with ER-positive breast cancer will ultimately relapse despite adjuvant tamoxifen with or without chemotherapy (10). Women with hormone receptor-positive disease that has metastasised to organ sites distant from the breast almost always relapse following first-line antihormonal therapy with tamoxifen. More effective antihormonal treatment for tamoxifen-resistant tumours are needed.

There is some evidence suggesting a worse outcome with tamoxifen for women with ER-positive tumours that lack progesterone receptor (PgR), and/or exhibit overexpression of growth factor receptors such as human epidermal growth factor receptors 1 and 2 (EGFR and HER-2/neu) (11,12). The observation that prolonged administration of tamoxifen may increase rather than decrease late recurrence rates (13) may be due to tamoxifen’s ability to act as a partial estrogen agonist in breast tissue under conditions of growth factor receptor up-regulation, which commonly occurs after prolonged tamoxifen use (11,12). AIs appear to be more effective than tamoxifen in ER-positive tumours regardless of PgR or growth factor receptor status (14,15).

Treatment with AIs produce frequent and durable responses in postmenopausal women previously treated with tamoxifen or endocrine ablative surgery, and AIs are more effective than tamoxifen in producing responses and delaying progression in first-line treatment of metastatic disease (16). A recent meta-analysis concluded that in women with metastatic breast cancer, AIs show a survival benefit when compared with other endocrine therapy (17).

**How are aromatase inhibitors currently used?**

The third-generation AIs are currently the preferred first-line treatment for metastatic hormone receptor-positive tumours and have all been approved by the US Food and Drug Administration for adjuvant use in postmenopausal women before or after surgery for ER-positive and/or PgR-positive breast cancer (18). Although anecdotal responses have been observed in women with ER- and PgR-negative tumours, in current clinical practice, only postmenopausal women with ER-positive and/or PgR-positive tumours are selected for treatment with AIs (9,16). There are several clinical studies evaluating the use of AIs in premenopausal women combined with ovarian...
suppression with a LH-releasing hormone (LHRH) analogue. AIs are generally not used off-label for premenopausal women except in special circumstances, such as prior tamoxifen failure or medical contraindications to tamoxifen. When AIs are used in premenopausal women they must be combined with surgical or medical ovarian ablation. Results with AIs in the adjuvant or neoadjuvant setting are detailed below.

**Neoadjuvant therapy with aromatase inhibitors vs. tamoxifen**

Systemic treatment administered before definitive surgery is termed neoadjuvant therapy and is often used in women who have clinically involved nodes or a tumour that is ≥ 3 cm. Under these circumstances the chance of occult metastatic disease is high, and the chance of breast conservation with a cosmetically acceptable outcome is low. Neoadjuvant treatment both increases the chance of breast conservation and promotes timely treatment of occult metastases. Pathological response to neoadjuvant chemotherapy is an important prognostic factor. Women with a pathological complete response in breast and lymph nodes to neoadjuvant chemotherapy have as much as a 95%, 5-year distant, disease-free survival (DFS) (19). Although pathological complete response rates after neoadjuvant chemotherapy are in the 20% or higher range for hormone receptor-negative tumours, they are rare with tumours that are hormone receptor-positive.

Neoadjuvant trials with antihormone therapy have generally shown that the chance of breast conservation is higher with AIs than tamoxifen and may be higher for AIs than for chemotherapy in women with hormone receptor positive tumours (19–22). In a trial comparing neoadjuvant letrozole with tamoxifen, the mammographic complete response rate with letrozole, although very low, was still higher than that observed for tamoxifen (20). In the Immediate Preoperative Anastrozole, Tamoxifen or Combined with Tamoxifen trial, women randomised to anastrozole alone were significantly more likely to have experienced sufficient tumour regression to be eligible for breast-conserving surgery than women randomised to tamoxifen or combined treatment (23). Neoadjuvant antihormonal therapy with an AI is a particularly attractive option for postmenopausal women who wish to attempt breast conservation and have strongly ER- and PgR-positive tumours that are ≥ 3 cm and have low proliferation rates.

**Adjuvant therapy with aromatase inhibitors vs. tamoxifen**

Clinical trials of AIs as adjuvant therapy have followed one of four approaches: (i) a head-to-head comparison of tamoxifen vs. an AI; (ii) extended adjuvant therapy following initial adjuvant therapy (5 years of an AI after 5 years of tamoxifen); (iii) switching to an AI for 2–3 years after 2–3 years of tamoxifen and (iv) combination therapy using both an AI and tamoxifen simultaneously. All AI approaches except the simultaneous combination of an AI and tamoxifen are associated with fewer breast cancer-related events than tamoxifen alone.

**Head-to-head comparisons of an aromatase inhibitor and tamoxifen**

The Anastrozole, Tamoxifen Alone or in Combination (ATAC) trial randomised more than 9000 women to 5 years of tamoxifen, anastrozole or both agents in combination. The combination treatment did not show a benefit and is not discussed further. Sixty-one per cent of women had no disease detected in their lymph nodes (referred to as node negative) at diagnosis. After 5 years of treatment, there was a significant improvement in DFS in the group of women treated with anastrozole alone regardless of tumour size, nodal status or use of adjuvant chemotherapy before the randomisation. There was a significant interaction with hormone receptor status: women who had ER-positive but PgR-negative tumours were likely to have a superior outcome with anastrozole, whereas women with tumours that were positive for both receptors did just as well with tamoxifen as with anastrozole. The absolute improvement in DFS with 5 years of anastrozole, compared with 5 years of tamoxifen, was 2.5% (p = 0.005). The incidence of contralateral breast cancer was reduced by 53% in women with hormone receptor-positive tumours. No overall survival benefit or significant reduction in deaths from breast cancer was demonstrated for anastrozole in this study. However, there appears to be an emerging survival benefit for women with ER-positive tumours who also had evidence of tumour cells in their draining lymph nodes (referred to as node positive) (24,25).

In the Breast International Group’s Femara-Tamoxifen trial, also known as BIG 1–98, 5 years of adjuvant letrozole was compared with 5 years of tamoxifen in postmenopausal women with ER-positive and/or PgR-positive breast cancer. Eventually, this trial was modified with the addition of two treatment groups in which women were either switched from tamoxifen to letrozole or from letrozole to tamoxifen after the initial 2 years of treatment (26). Approximately 8000 patients were randomised to receive tamoxifen or letrozole as their initial therapy. Fifty-nine per cent of women were node negative, and the median age was 61. At a median follow-up of slightly more than 2 years, there was a
significant 3.4% absolute improvement in DFS with letrozole compared with tamoxifen. Women with PgR-positive and PgR-negative cancer appeared to benefit equally from letrozole compared with tamoxifen. An approximate 50% reduction in risk of contralateral breast cancer was observed. No significant overall survival benefit was reported, although there was a numeric reduction in deaths from breast cancer and an increase in deaths because of other causes in the group treated initially with letrozole (26). These results were recently updated analysing only those women randomised to 5 years of letrozole vs. placebo. At a median follow-up of 51 months there continues to be a 3% absolute improvement in DFS (18% relative reduction) following letrozole with no improvement in overall survival (27).

The ongoing Tamoxifen Exemestane Adjuvant Multi-institutional (TEAM) trial compares exemestane with tamoxifen as first-line adjuvant treatment. The TEAM trial is designed to compare DFS in patients treated with exemestane vs. tamoxifen at 2.75 years, and to compare DFS in patients treated with 5 years of up-front exemestane vs. tamoxifen for 2.5–3 years followed by 2–2.5 years of exemestane. Enrolment was completed in January 2006 \( (n = 9786) \). We are awaiting the efficacy results of this trial.

### Aromatase inhibitors as extended endocrine adjuvant therapy

Given the appreciable late recurrence rates in women with ER-positive breast cancer following 5 years of adjuvant tamoxifen, the MA.17 trial was designed to determine whether 5 years of letrozole (after 5 years of adjuvant tamoxifen) would improve DFS compared with placebo. At a median follow-up of 2.4 years from the time of randomisation, letrozole improved DFS, compared with placebo, by a relative value of 43% and an absolute value of 6%. This was significant regardless of nodal status (28). The trial was unblinded, with women who received placebo given open-label treatment with letrozole on request (28). In an update of this study, a significant reduction in death from any cause was noted for node-positive women receiving letrozole (29). Incidence of menopause-related symptoms, new onset of osteoporosis, arthralgias and alopecia (generally minimal to mild) were all higher for women randomised to letrozole compared with placebo. There was no increase in the rate of bone fracture. There were some specific quality of life domains which were significantly worse with letrozole, including physical functioning, bodily pain, vitality, vasomotor symptoms and sexuality (30).

### Switching therapy

The switching strategy was designed to: (i) combine the apparent superior efficacy of AIs with tamoxifen’s favourable effects on bone and (ii) expose tumour cells to anti-hormonal therapies with two different mechanisms of action. Several adjuvant trials were designed in which, after 2–3 years of adjuvant tamoxifen, women were randomised to continue taking tamoxifen for another 2–3 years or switch to an AI. One such trial, the Intergroup Exemestane Study (IES), randomised 4742 postmenopausal women after 2–3 years of tamoxifen to exemestane 25 mg/day or to continued tamoxifen of sufficient duration to complete a 5-year course of adjuvant therapy (31). Fifty-one per cent of patients were node negative at baseline, and 81% were known to have ER-positive breast cancer. At a median follow-up of 30.6 months, exemestane was associated with a 32% reduction in risk of local or metastatic recurrence, contralateral breast cancer, or death, for an absolute benefit of 4.7% in terms of DFS compared with tamoxifen (31). A recent update at 58 months showed similar improvement in DFS in both the intent-to-treat (24%) and ER-positive/unknown population (26%). A 45% relative reduction in the incidence of contralateral breast cancer was observed. A 17% relative increase in overall survival \( (p = 0.05) \) was reported for women randomised to switch to exemestane compared with those remaining on tamoxifen if their tumours were ER-positive or ER unknown (32). Quality of life measured at 3- to 6-month intervals during the first 24 months was similar for women taking exemestane or tamoxifen (33).

In other switching trials, such as the Italian Tamoxifen Arimidex (ITA) trial and the Austrian Breast and Colorectal Study Group 8 (ABCSG 8)/Arimidex-Nolvadex (ARNO 95) combined analysis, switching to anastrozole after 2 years of tamoxifen was compared with continued tamoxifen treatment. A 39% relative improvement in DFS \( (p = 0.049) \) and 52% improvement in overall survival were seen at a median follow-up of 30 months in the ABCSG 8/ARNO 95. Improvement in DFS was observed for ITA (34,35).

In summary, all the adjuvant trials in postmenopausal women – whether they involved initial head-to-head comparison with tamoxifen (ATAC, BIG 1–98), switching to an AI after 2–3 years of tamoxifen (IES, ITA and ABCSG 8/ARNO 95), or administering 5 years of an AI after 5 years of tamoxifen – show improvement in DFS favouring the AI. An overall survival benefit is emerging in at least two of the switching trials in women randomised to 2–3 years of an AI following 2–3 years of tamoxifen vs. continuing on tamoxifen (32,35). No
significant overall survival benefit has been demonstrated to date for up-front AI administration with letrozole or anastrozole or extended adjuvant therapy with letrozole, although node-positive women appear to show a survival benefit. Follow-up in these trials is short, and an overall survival advantage is likely with up-front AI use. The lack of an early overall survival advantage with AIs in the up-front setting compared with the switch setting may be due to the fact that the switch trials, by excluding women who relapse on tamoxifen in the first 2–3 years, enroll women who are most likely to respond to antihormone therapy. At present, the American Society of Clinical Oncology Technical Assessment recommends that postmenopausal women with receptor-positive breast cancer receive an AI as part of their adjuvant therapy, either as initial therapy, as part of a switching strategy, or after 5 years of tamoxifen (18).

There is no clear advantage to one AI vs. another at the present time. Oncologists often select an AI depending on the type of adjuvant strategy they wish to employ. Several head-to-head trials comparing one AI to another in the adjuvant setting are ongoing. These include trials of anastrozole vs. exemestane and anastrozole vs. letrozole.

### Use of aromatase inhibitors in premenopausal women

Responses have been observed in premenopausal women with concomitant goserelin and AI treatment following tamoxifen failure (36,37). This concept is also being tested in the adjuvant setting with the Suppression of Ovarian Function (SOFT) and Tamoxifen or Exemestane Plus Ovarian Ablation (TEXT) trials. In the SOFT trial, women who are premenopausal after any adjuvant chemotherapy and have ER-positive tumours are randomised to tamoxifen, tamoxifen plus an LHRH analogue or exemestane plus the LHRH analogue (other types of ovarian ablation are also allowed). In the TEXT trial, premenopausal women who may or may not have received chemotherapy are randomised to receive tamoxifen or exemestane, both with an LHRH analogue. The TEXT trial is nearing completion of accrual. It is not clear whether an AI with ovarian ablation will be as good as or better than tamoxifen with or without ovarian ablation at this time. If an AI is given to a premenopausal woman outside of these ongoing trials ovarian ablation with oophorectomy or ovarian suppression with an LHRH analogue must be given. If ovarian suppression with an LHRH analogue is chosen, serum estradiol levels must be monitored regularly to ensure that they remain in the postmenopausal range.

### Adverse event profile of aromatase inhibitors compared with tamoxifen

The adverse event profile for AIs differs from that of tamoxifen. There is no increase in uterine cancers or thromboembolic events as is observed with tamoxifen, but with the exception of hot flushes. Women taking AIs are more likely to complain of symptoms related to estrogen deprivation. Women taking AIs are also more likely to report musculoskeletal adverse events than women taking tamoxifen. These are considered in detail below.

### Gynaecological sequelae

Use of AIs is associated with a higher frequency of vaginal dryness, loss of libido and painful intercourse than is tamoxifen. There are fewer instances of vaginal bleeding and endometrial cancer with AIs than with tamoxifen (30,33,38). AIs are associated with hot flushes, but the proportion of women who exhibit vasomotor instability may be less than that seen with tamoxifen treatment (31,39). Younger age at initiation of treatment is associated with increased frequency of hot flushes (40).

### Musculoskeletal effects

Studies of tamoxifen in postmenopausal women have shown reduction in bone turnover markers and an increase in bone density and the opposite effects with AIs (41–44). These differential effects are not surprising because tamoxifen exerts partial estrogen agonist effects on bone in postmenopausal women, and osteoporosis has been strongly associated with the low serum estrogen levels that occur following AI administration (45). Although a head-to-head comparison of the three third-generation AIs in the Letrozole, Exemestane, Anastrozole Pharmacodynamics study has shown a similar effect on markers of bone turnover for all three drugs (46), it has also been suggested that exemestane may be associated with less of a deleterious effect than is seen with the other third-generation AIs (47). Additional data are expected from a bone substudy in MA.27, an adjuvant trial comparing anastrozole with exemestane.

In adjuvant studies, all three third-generation AIs – anastrozole, letrozole and exemestane – have shown an increased risk of bone fracture compared with tamoxifen. The absolute differences, while statistically significant in the ATAC trial of anastrozole vs. tamoxifen and the BIG 1–98 trial of letrozole vs. tamoxifen, were only 1–4%. Most fractures were in the spine and not the hip (27,48). The difference in fracture rate approached, but did not reach, statistical significance in the IES trial (3.1% for women switching to exemestane vs. 2.3% in women contin-
Hormonal agents for treatment and prevention of breast cancer

Thromboembolic and cardiovascular effects

Aromatase inhibitors do not increase the risk of deep venous thrombosis; this differs from tamoxifen, for which the risk of deep venous thrombosis and pulmonary embolism is increased approximately twofold (57,58). Further, except for a higher frequency of occurrence in women over 50 and those with high body mass index, there does not appear to be an easily identified predisposing factor behind the majority of episodes of deep venous thrombosis associated with tamoxifen (59).

Aromatase inhibitors in adjuvant trials have been associated with an increase in ischaemic cardiovascular events and a numeric, but not statistically significant increase in cardiac deaths when compared with tamoxifen (25,30,31), but not when compared with placebo (29). AIs do not have a substantial effect on lipid metabolism (39,58). It is possible that, if there is an intrinsic adverse effect of AIs on ischaemic heart disease, it might be due to estrogen depletion in the coronary arteries leading to loss of the vasodilatory response of estrogen to stress (60). Alternatively, the observation might stem from a small cardio-protective benefit from tamoxifen rather than a deleterious effect of AIs. With the exception of triglycerides, tamoxifen has a favourable effect on the serum lipid profile (1) and tamoxifen has also been observed to improve endothelial function and reduce carotid intima–media thickness in postmenopausal women (61). Despite tamoxifen’s favourable effects on some lipid and endothelial parameters, there is as yet no conclusive evidence that tamoxifen exhibits cardioprotective effects (62). The lack of significant cardiovascular benefit in most randomised trials for tamoxifen may be due to an increase in triglycerides and clot promoting proteins, which offset the beneficial cardiovascular effects of tamoxifen (1,59). An additional factor might be the widespread use of statins, which would obscure tamoxifen’s favourable effects on cholesterol. In the ATAC trial, 4.1% of participants randomised to anastrozole vs. 3.4% of those randomised to tamoxifen died from ischaemic heart disease (25). In the IES trial, at 3-year follow-up, a higher number of cardiovascular deaths were reported for exemestane than for tamoxifen (1.1% vs. 0.8%) (31). In the BIG 1–98 trial, 2.5% of women randomised to letrozole had serious or fatal cardiac events compared with 1.1% taking tamoxifen; this was highly significant (27). There were also twice as many cardiac deaths with letrozole than with tamoxifen (13 vs. 6), but given the small number of events, the difference was not statistically significant.

Because the proportional differences in cardiac deaths observed in women randomised to AI vs. tamoxifen are < 1%, a potential increase in cardiovascular events is not likely to be a major concern for women undergoing cancer therapy with an AI. However, enthusiasm for AI use in the primary pre-

Bisphosphonates can be used to prevent the bone mineral loss observed with AIs. This strategy was successfully used in the Zometa–Femara Adjuvant Synergy trials, and the Austrian Breast and Colorectal Cancer Study Group trial 12, in which an intravenous bisphosphate, zolendronic acid, was administered every 6 months for the duration of AI therapy (49,50). Vitamin D supplementation is advisable in women with serum 25-OH vitamin D levels < 30 ng/ml because women with baseline vitamin D insufficiency are at an increased risk of bone loss when receiving AIs (51).

In randomised studies, arthralgias/myalgias have been reported significantly more frequently in women randomised to AIs than in those randomised to tamoxifen or placebo. The absolute frequency varies tremendously from trial to trial (5.4–37% for AIs vs. 3.6–26% for tamoxifen or placebo), which in turn probably reflects the method used to record the symptoms. The incidence of arthralgias and myalgias appear to be about two-thirds higher with an AI than with tamoxifen or placebo but usually improves with time (38). Two small studies have shown that women taking AIs for cancer therapy often have deficient or suboptimal 25-OH vitamin D levels in their serum (51,52). Improvements in myalgias and arthralgias were observed in a high proportion of women with deficient or suboptimal levels of vitamin D who were given prescription-strength vitamin D for 12 weeks (52). Serum 25-OH vitamin D is used to assess adequacy of total body vitamin D stores (53) and levels should be checked prior to starting AI treatment to make sure they are in the optimal range of 30–50 ng/ml (53–55). In general, each additional 1000 IU of vitamin D3 can be expected to increase 25-OH-D serum levels by 10 ng/ml. The addition of celecoxib 400 mg bid to exemestane reduced arthralgias and improved response rates in a placebo-controlled trial in women with metastatic disease (56). Prospective trials are under way to assess the prevalence of vitamin D deficiency in women undergoing adjuvant therapy with AIs, correlation with the development of myalgias/arthritis and the relief of symptoms with vitamin D replacement.
vention setting will be limited if AIs are found to be associated with a higher number of cardiac events compared with placebo or tamoxifen.

Management and prevention of adverse events

As AI use becomes more common, internists will undoubtedly be asked by their patients for help with management and prevention of adverse events, although the relative risks and benefits of AIs vs. other hormonal therapy will hopefully have been discussed by the patient’s oncologist.

For vasomotor symptoms, non-hormonal methods such as selective serotonin reuptake inhibitors (SSRIs), gabapentin or clonidine should be tried first (63). In doses commonly needed for relief of hot flushes (75 mg venlafaxine, 20 mg fluoxetine and 300–900 mg gabapentin), side effects for these medications include drowsiness, dry mouth and dyspepsia. Use of SSRIs may also contribute to the loss of sexual interest.

Vaginal dryness that is not ameliorated with lubricants may be treated with poorly absorbed vaginal estrogens, such as oestradiol vaginal rings or tablets. However, a small study showed a significant increase in serum estrogen levels following use of these preparations (64). A weak preparation (1%) of testosterone with 2 mg of oestradiol (1 g administered 2–3 times weekly) is often effective for improving vaginal dryness, dyspareunia and libido. When women are taking AIs, testosterone cannot be readily converted to estradiol. Estradiol is a very weak estrogen and likewise cannot be converted to estradiol (65). There is little information regarding the safety of this practice, particularly in women with prior breast cancer (66).

Aromatase inhibitors for breast cancer prevention

Tamoxifen fails to prevent ER-negative breast cancer, and one-third or more of ER-positive breast cancers (67–70). The incomplete efficacy, increased risk of serious adverse events, and the lack of survival benefit with tamoxifen given as primary prevention (66–70) fuels the effort to develop safer and more effective primary-prevention strategies. The superior DFS observed for AIs compared with tamoxifen in the adjuvant setting combined with the lack of increase in thromboembolic events or uterine cancer has led to the initiation of multiple primary-prevention trials in high-risk women without prior breast cancer. Currently, there are several major multi-institutional primary-prevention trials in postmenopausal women in which an AI is being compared with placebo (Table 2).

Of serious concern for prevention is the potential for increase in risk of bone fracture and cardiovascular disease related to long-term estrogen depletion with AIs. However, arthralgias, fatigue, dyspareunia, reduced libido and hot flushes may result in poor uptake and/or compliance. Ongoing phase III prevention trials will define the incidence of these adverse events relative to placebo in a healthy population, and potential solutions to avoid some of these problems in the prevention setting are already being explored.

One small study indicates that bone mineral loss after AIs is primarily limited to women with insufficient 25-OH vitamin D levels (71). Given the importance of adequate vitamin D in health, practitioners should strive to achieve 25-OH vitamin D levels of at least 30 ng/ml (55,72). Bisphosphonates have been found effective in preventing AI- and cancer-therapy-related bone mineral loss in the adjuvant setting (73,74). Along with exercise and appropriate supplementation of calcium and vitamin D, bisphosphonates could be used along with AIs to prevent bone loss. Very low-dose estradiol (0.015 mg estradiol patch replaced twice weekly) increased serum estradiol to a median of 12 pmol and may be effective in reducing the increased bone turnover associated with AI use (75).

Statins could be used along with AIs to improve both lipid profiles and endothelial function. There is

| Trial                                      | Agents studied         | Duration studied (years) |
|--------------------------------------------|------------------------|--------------------------|
| International Breast Cancer Intervention Study II | Anastrozole vs. placebo | 5                        |
| Aromasin Prevention Study                   | Exemestane vs. placebo  | 3                        |
| National Cancer Institute of Canada Clinical Trials | Exemestane vs. placebo  | 5                        |
| Group MAP.3 Breast Cancer Prevention Trial  |                        |                          |

AIs, aromatase inhibitors.
also a suggestion that long-term use of a lipophilic statin might reduce breast cancer risk (76), but results in case–control studies are mixed (77–79). However, because both statins and AIs are metabolised in the liver, pharmacological and pharmacodynamical studies need to be completed to better understand how concomitant administration might affect levels of both drugs.

Approximately one-quarter of perimenopausal and postmenopausal women take hormone replacement therapy for some period of time during menopause or menopause transition (80). Although other drugs give partial relief of symptoms associated with the climacteric, none is as effective as hormone replacement (81). The Women’s Health Initiative (WHI) indicates a nonsignificant increase in the risk of breast cancer and coronary heart disease for women taking combined oral equine estrogen plus a progestin after 5 years. However, there was no increase in breast cancer risk in the WHI for women taking estrogen alone at a median follow-up time of ~7 years (82,83). In fact, updated results indicate that women aged 50–59 randomised to estrogen alone had a nonsignificant reduction in breast cancer and coronary heart disease. Further, for women aged 50–59 randomised to estrogen alone or combined estrogen plus progestin there was a significant 30% reduction in overall mortality compared with those randomised to placebo (84,85). The Million Women Study showed a modest increase in risk of breast cancer for hormone replacement therapy given by any route with the exception of vaginal hormones. Similar to the WHI, women taking estrogen and a progestin had a higher relative risk than those receiving estrogen alone (86). Few prevention options are available for those women who need hormone replacement for the management of menopausal symptoms and who are at increased risk for breast cancer because of family history or other factors.

Tamoxifen and hormone replacement (usually transdermal) are commonly prescribed together in Europe, but this is generally not performed in the USA (87). Furthermore, updated analyses of the three major primary prevention trials of tamoxifen vs. placebo in which hormone replacement was allowed have yielded conflicting results. The Italian prevention trial conducted predominately in average risk hysterectomised women found a reduced risk of ER+ breast cancer with tamoxifen only in those women at increased risk because of hormone replacement or other factors (69). The Royal Marsden trial showed a reduced incidence of ER+ breast cancer whether women took hormone therapy or not. However, the International Breast Cancer Intervention Study 1 trial results indicated tamoxifen was not effective in women beginning hormone replacement therapy (HRT) during study (68–70).

Preclinical studies indicate that AIs might be effective in reducing the risk of breast cancer in hormonally intact animals under circumstances in which breast aromatase is up-regulated (88). In studies of postmenopausal women, breast estradiol levels have been found to be 10– to 50-fold higher than serum levels, and aromatase – which is up-regulated in proliferative breast disease – is responsible for much of this local synthesis (89,90). We have performed a 6-month pilot study of letrozole in high-risk women who continued to take their hormone replacement during the study period. An approximate two-thirds reduction in breast tissue proliferation (Ki-67) was observed after 6 months of letrozole. There was no increase in hot flushes or arthralgias for the majority of women in the trial (91). The concept of using an AI in women already receiving hormone replacement therapy will be explored further in a placebo-controlled, randomised, proof-of-principle trial in which change in Ki-67 in benign breast tissue is the primary end-point. In this ongoing study, the change in bone turnover markers and the cardiovascular risk biomarkers will also be explored.

**Overcoming resistance to aromatase inhibitors**

Even with an initial response to treatment, for women with metastatic disease, resistance eventually develops to AIs and clinical regrowth of tumour is observed. In most cases, the resistant cancer continues to be ER positive. There are several mechanisms of resistance demonstrated in animal models. These include: (i) development of hypersensitivity of the ER to very low levels of estrogen; (ii) up-regulation of growth factor receptors and/or associated signalling pathways (HER-2, EGFR and insulin growth factor receptor (IGFR)) (92,93). Reduction in the level of ER expression would theoretically reduce the sequelae of ER hypersensitivity and could be accomplished by increasing ER ubiquitisation with a drug such as fulvestrant, an ER down-regulator (94). Results from animal models suggest that the AI letrozole plus fulvestrant is more effective than either alone (93). Fulvestrant is often effective as antihormonal therapy following response and progression on an AI and is equally effective as anastrozole in women with metastatic disease who have previously been treated with tamoxifen (94,95). Fulvestrant plus anastrozole is currently being compared with anastrozole alone in metastatic disease in the co-operative group setting. The use of short courses of physiological or pharmacological doses of estradiol to induce apoptosis in breast
cancer cells with a hypersensitive ER in women whose tumours are resistant to multiple types of endocrine therapy including AIs has been suggested based upon preclinical models (96,97). Combination regimens of AIs and several types of growth factor receptor or activated pathway inhibitors are being explored (98–100).

Summary

The third-generation AIs are now preferred therapy for postmenopausal women with hormone receptor-positive tumours in both the early and metastatic settings. Switching from adjuvant tamoxifen to an AI (exemestane or anastrozole) after 2–3 years of tamoxifen has shown superior DFS and overall survival compared with continuing on tamoxifen. Using anastrozole or letrozole instead of adjuvant tamoxifen as initial therapy (with or without prior adjuvant chemotherapy) has also shown superior DFS. Finally, for women completing 5 years of tamoxifen, extended adjuvant antihormonal therapy with letrozole has shown a reduced recurrence rate, particularly for node-positive patients. American Society of Clinical Oncology guidelines recommend that an AI be included in a woman’s adjuvant regimen if she has ER-positive and/or PgR-positive breast cancer. The decision to use AI as initial endocrine therapy, as opposed to switching to an AI after 2–3 years of tamoxifen therapy, is likely to be guided by the tumour characteristics. Patients who have ER-positive tumours with unfavourable characteristics, such as HER-2 positivity, PgR negativity or nodal positivity, are likely to be selected for immediate AI therapy. However, patients with ER-positive tumours without unfavourable characteristics are likely to be selected for tamoxifen treatment for 2–3 years before taking an AI for 2–3 years. Several ongoing clinical trials are examining the use of AIs in women at an elevated risk of developing breast cancer. Critical to the ultimate success of AIs in both the adjuvant and preventive settings will be management of adverse events, particularly bone mineral density loss, arthralgias and gynaecological sequelae.

Acknowledgements

Editorial support was provided by Complete Healthcare Communications, Inc., and was funded by Pfizer Inc.

References

1 Fabian CJ, Kimler BF. Selective estrogen-receptor modulators for primary prevention of breast cancer. J Clin Oncol 2005; 23: 1644–55.
2 Simpson ER, Davis SR. Minireview: aromatase and the regulation of estrogen biosynthesis—some new perspectives. Endocrinology 2003; 142: 4589–94.
3 MacNeill FA, Jones AL, Jacobs S et al. The influence of amino-glutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br J Cancer 1992; 66: 692–7.
4 Dowsett M, Stein RC, Mehta A, Coombes RC. Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clin Endocrinol (Oxf) 1999; 52: 623–34.
5 van der Wall E, Donker TH, de Frankrijker D et al. Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women. Cancer Res 1993; 53: 4563–6.
6 Dowsett M, Jones A, Johnston SR et al. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal women with breast cancer. Clin Cancer Res 1995; 1: 1511–7.
7 Geisler J, King N, Dowsett M et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996; 74: 1286–91.
8 Geisler J, King N, Anker G et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998; 4: 2089–93.
9 Winer EP. Optimizing endocrine therapy for breast cancer. J Clin Oncol 2003; 21: 1609–10.
10 Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687–717.
11 Hu JC, Mokbel K. Does c-erbB2/HER2 overexpression predict adjuvant tamoxifen failure in patients with early breast cancer? Eur J Surg Oncol 2001; 27: 335–7.
12 Osborne CK, Bardou V, Hopp TA et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003; 95: 353–61.
13 Fisher B, Digang A, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001; 93: 684–90.
14 Dowsett M, Martin LA, Smith I, Johnston S. Mechanisms of resistance to aromatase inhibitors. J Steroid Biochem Mol Biol 2005; 95: 167–72.
15 Ellis MJ, Coop A, Singh B et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 2003; 63: 6523–31.
16 Ingle JN, Suman VJ. Aromatase inhibitors for therapy of advanced breast cancer. J Steroid Biochem Mol Biol 2005; 95: 113–9.
17 Gibson LJ, Dawson CK, Lawrence DH, Bliss JM. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev 2007; CD003370.
18 Winer EP, Hadis C, Burstein HI et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status Report 2004. J Clin Oncol 2005; 23: 619–29.
19 Carey LA, Metzger R, Dees EC et al. American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst 2005; 97: 1137–42.
20 Eiermann W, Paepke S, Appelstaedt J et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter trial. Ann Oncol 2001; 12: 1527–32.
Hormonal agents for treatment and prevention of breast cancer

21 Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neo-adjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808–16.

22 Semiglazov VF, Semiglazov V, Ivanov V et al. The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in post-menopausal women with ER-positive breast cancer. J Clin Oncol 2004; 22: 519.

23 Smith IE, Dowsett M, Ebbs SR et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005; 23: 5108–16.

24 Howlitt A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005; 365: 60–2.

25 Buzdar AU, Guastalla JP, Nabholtz JM et al. Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial. Cancer 2006; 107: 472–80.

26 Thurlimann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747–57.

27 Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25: 486–92.

28 Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793–802.

29 Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from the NSCCTG MA17. J Natl Cancer Inst 2005; 97: 1262–71.

30 Whelan TJ, Goss PE, Ingle JN et al. Assessment of quality of life in MA17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005; 23: 6931–40.

31 Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081–92.

32 Coombes RC, Kilburn L, Snowden C et al. Survival and quality of life of postmenopausal women treated with exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369: 559–70.

33 Fallowfield L, Bliss MJ, Porter LS et al. Quality of life in the Intergroup Exemestane Study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 2006; 24: 910–7.

34 Boccadoro F, Rubagotti A, Puntoni M et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005; 23: 5138–47.

35 Kaufmann M, Jonat W, Hilfrich J et al. Survival benefit of switching to anastrozole after 2 years’ treatment with tamoxifen versus continued tamoxifen therapy: the ARNO 95 Study. J Clin Oncol 2006; 24: 547.

36 Forward DP, Cheung KL, Jackson L, Robertson JF. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 2004; 90: 590–4.

37 Carlson R. Goserelin plus anastrozole for treatment of premenopausal women with hormone receptor positive recurrent/metastatic breast cancer [Abstract]. Breast Cancer Res Treat 2004; 88: S237–8.
Hormonal agents for treatment and prevention of breast cancer

56 Freyer G, Debled M, Gray JF et al. Colecizib (Ce) + exemestane (Ex) versus placebo + Ex in post-menopausal (PM) metastatic breast cancer (MBC) patients (pts): a double-blind phase III GINECO study. J Clin Oncol 2006; 24: 565.

57 Atalay G, Diriş L, Biganzoli L et al. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, ’Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients’. Am J Clin Oncol 2004; 27: 211–7.

58 Bunded NJ. The effects of aromatase inhibitors on lipids and thrombosis. Br J Cancer 2005; 93: S23–7.

59 Stamatelopoulos KS, Lekakis JP, Poulakaki NA et al. Tamoxifen improves endothelial function and reduces carotid intima-media thickness in postmenopausal women. Am Heart J 2004; 147: 1093–9.

60 Braithwaite RS, Chlebowski RT, Lau J et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Clin Oncol Med 2003; 18: 937–47.

61 Barrett-Connor E, Mosca L, Collins P et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125–37.

62 Blumenthal RS, Baranowski B, Dowsett SA. Cardiovascular effects of raloxifene: the arterial and venous systems. Am Heart J 2004; 147: 783–9.

63 Chlebowski RT, Kim IA, Col NF. Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy. Semin Oncol 2003; 30: 776–88.

64 Kendall A, Dowsett M, Folked R, Smith I. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006; 17: 584–7.

65 Bachmann GA, Leiblum SR. The impact of hormones on menopausal sexuality: a literature review. Menopause 2004; 11: 120–30.

66 Somboonporn W, Davis SR. Testosterone effects on the breast: implications for testosterone therapy for women. Endocr Rev 2004; 25: 574–88.

67 Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371–88.

68 Cuzick J, Forbes JF, Sepstak I et al. Long-term results of tamoxifen prophylaxis for breast cancer – 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007; 99: 272–82.

69 Veronesi U, Maisonneuve P, Rotmensz N et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 2007; 99: 727–37.

70 Powles TJ, Ashley S, Tidy A, Smith JE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007; 99: 283–90.

71 Lomning P, Geiser J, Krag LE et al. Vitamin D deficiency: a threat to bone health in breast cancer patients during adjuvant treatment with aromatase inhibitors. J Clin Oncol 2006; 24 (18S): 554.

72 Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007; 85: 1586–91.

73 Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21: 4042–57.

74 Brutsky A, Bunded N, Coleman R et al. An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (Breast Cancer Res Treat 2006; 100 (Suppl. 1): S25 (abstract 107).

75 Kendall A, Smith I, Folked R, Dowsett M. Aromatase inhibition and very low dose estradiol add-back: a pilot study for novel breast cancer prevention [Abstract]. J Clin Oncol 2006; 24: 1014.

76 Campbell MJ, Esserman LJ, Zhou Y et al. Breast cancer growth prevention by statins. Cancer Res 2006; 66: 8707–14.

77 Eliassen AH, Colditz GA, Rosner B et al. Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med 2005; 165: 2264–71.

78 Kumar AS, Esserman LJ. Statins: health-promoting agents show promise for breast cancer prevention. Clin Breast Cancer 2005; 6: 455–9.

79 Bonovas S, Filiosussi K, Tsavaris N, Sitras NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 2005; 23: 8606–12.

80 National Institutes of Health. National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Ann Intern Med 2005; 142: 1003–13.

81 Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 2004; 291: 1610–20.

82 Rossoow JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321–33.

83 Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–12.

84 Rossoow JE, Prentice RL, Manson JE et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297: 1465–77.

85 Stefanick ML, Anderson GL, Margolis KL et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006; 295: 1647–57.

86 Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–27.

87 Vogel VG. Reducing the risk of breast cancer with tamoxifen in women at increased risk. J Clin Oncol 2001; 19: 875–82.

88 Tekmal RR, Liu YG, Nair HB et al. Estrogen receptor alpha is required for mammary development and the induction of mammary hyperplasia and epigenetic alterations in the aromatase transgenic mice. J Steroid Biochem Mol Biol 2005; 95: 9–15.

89 Erster VL, Wrensch MR, Petrakis NL et al. Benign and malignant breast diseases: initial study results of serum and breast fluid analyses of endogenous estrogens. J Natl Cancer Inst 1987; 79: 949–60.

90 Santen RJ, Martel J, Hosagland M et al. Demonstration of aromatase activity and its regulation in breast tumor and benign breast fibroblasts. Breast Cancer Res Treat 1998; 49 (Suppl. 1): S93–9; discussion S109–19.

91 Fabian CJ, Kimler BF, Zalles CM et al. Reduction in proliferation with six months of letrozole in women on hormone replacement therapy. Breast Cancer Res Treat 2007; doi: 10.1007/s10549-006-9476-5.

92 Jordan VC. SERMs: meeting the promise of multifunctional medicines. J Natl Cancer Inst 2007; 99: 350–6.

93 Brodie A, Sabnis G, Macedo L. Xenograft models for aromatase inhibitor studies. J Steroid Biochem Mol Biol 2007; doi: 10.1016/j.jsbmb.2007.05.022.

94 Robertson JF, Osborne CK, Howell A et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003; 98: 229–38.

95 Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AM. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res 2005; 65: 5439–44.

96 Lomning PE, Taylor PD, Anker G et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 2001; 67: 111–6.

Journal compilation © 2007 Blackwell Publishing Ltd Int J Clin Pract, December 2007, 61, 12, 2051–2063

© 2007 The Author
97 Lewis JS, Meeke K, Osipo C et al. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. *J Natl Cancer Inst* 2005; 97: 1746–59.

98 Marcom PK, Isaacs C, Harris L et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. *Breast Cancer Res Treat* 2007; 102: 43–9.

99 Lane HA, Lebwohl D. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program. *Semin Oncol* 2006; 33 (2 Suppl. 7): S18–25.

100 Brueggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase inhibitors in the treatment of breast cancer. *Endocr Rev* 2005; 26: 331–45.

101 FEMARA® (Letrozole Tablets). *Full Prescribing Information*. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2005.

102 ARIMIDEX® (Anastrozole Tablets). *Full Prescribing Information*. Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2005.

103 Aromasin® (Exemestane Tablets). *Full Prescribing Information*. New York, NY: Pharmacia & Upjohn Co., Division of Pfizer Inc., 2005.

104 Brueggemeier RW. Overview of the pharmacology of the aromatase inhibitor exemestane. *Breast Cancer Res Treat* 2002; 74: 177–85.

*Paper received May 2007, accepted August 2007*